Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with Cyclophosphamide and Lenalidomide in Relapsed Multiple Myeloma
NCT03191981Phase 2Withdrawn
- Sponsor
- University of Leeds
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by University of Leeds. Planned start Aug 2017; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03191981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191981.